# Tivantinib in Treating Patients With Metastatic Prostate Cancer

> **NCT01519414** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 78 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo
- **DRUG:** Tivantinib

## Key facts

- **NCT ID:** NCT01519414
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-11
- **Primary completion:** 2015-08-18
- **Final completion:** 2015-08-18
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01519414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01519414, "Tivantinib in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01519414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*